Sanofi [SNY] is 8.60% higher this YTD. Is it still time to buy?


Sanofi [NASDAQ: SNY] surged by $0.07 during the normal trading session on Thursday and reaching a high of $54.66 during the day while it closed the day at $54.41. The company report on April 28, 2022 that Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1.

Sanofi stock has also loss -1.48% of its value over the past 7 days. However, SNY stock has inclined by 2.93% in the 3 months of the year. Over the past six months meanwhile, it has gained 9.76% and gained 8.60% year-on date.

The market cap for SNY stock reached $140.60 billion, with 2.51 billion shares outstanding and 2.25 billion shares in the current float. Compared to the average trading volume of 2.08M shares, SNY reached a trading volume of 3031911 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Sanofi [SNY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNY shares is $66.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNY stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

SVB Leerink have made an estimate for Sanofi shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 27, 2021. While these analysts kept the previous recommendation, Deutsche Bank raised their target price to Sell. The new note on the price target was released on January 15, 2021, representing the official price target for Sanofi stock.

The Average True Range (ATR) for Sanofi is set at 1.04, with the Price to Sales ratio for SNY stock in the period of the last 12 months amounting to 3.31. The Price to Book ratio for the last quarter was 1.83, with the Price to Cash per share for the same quarter was set at 4.23.

SNY stock trade performance evaluation

Sanofi [SNY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.48. With this latest performance, SNY shares gained by 5.81% in over the last four-week period, additionally plugging by 9.76% over the last 6 months – not to mention a rise of 3.23% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNY stock in for the last two-week period is set at 52.11, with the RSI for the last a single of trading hit 49.16, and the three-weeks RSI is set at 53.25 for Sanofi [SNY]. The present Moving Average for the last 50 days of trading for this stock 52.77, while it was recorded at 54.29 for the last single week of trading, and 50.98 for the last 200 days.

Sanofi [SNY]: An insightful look at the core fundamentals

Sanofi’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.40.

Earnings per share (EPS) analysis for Sanofi [SNY] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sanofi go to 10.30%.

Sanofi [SNY]: Insider Ownership positions

There are presently around $13,306 million, or 9.90% of SNY stock, in the hands of institutional investors. The top three institutional holders of SNY stocks are: DODGE & COX with ownership of 93,402,049, which is approximately -0.763% of the company’s market cap and around 16.40% of the total institutional ownership; FISHER ASSET MANAGEMENT, LLC, holding 17,981,595 shares of the stock with an approximate value of $977.12 million in SNY stocks shares; and FMR LLC, currently with $934.93 million in SNY stock with ownership of nearly 3.171% of the company’s market capitalization.

Positions in Sanofi stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 318 institutional holders increased their position in Sanofi [NASDAQ:SNY] by around 14,286,516 shares. Additionally, 231 investors decreased positions by around 6,639,709 shares, while 122 investors held positions by with 223,930,237 shares. The mentioned changes placed institutional holdings at 244,856,462 shares, according to the latest SEC report filing. SNY stock had 93 new institutional investments in for a total of 3,620,007 shares, while 51 institutional investors sold positions of 889,748 shares during the same period.